D.E. Shaw & Co
RGNX icon

D.E. Shaw & Co’s Regenxbio RGNX Stock Holding History

D.E. Shaw & Co’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.4M Buy
286,001
+217,613
+318% +$2.29M ﹤0.01% 2777
2025
Q4 		$985K Buy
+68,388
New +$852K ﹤0.01% 3558
2025
Q1 		– Sell
-63,377
Closed -$490K – 4657
2024
Q4 		$490K Buy
63,377
+8,271
+15% +$77.7K ﹤0.01% 3631
2024
Q3 		$578K Sell
55,106
-87,563
-61% -$1.07M ﹤0.01% 3616
2024
Q2 		$1.67M Sell
142,669
-13,491
-9% -$210K ﹤0.01% 2820
2024
Q1 		$3.29M Sell
156,160
-1,480
-0.9% -$26.3K ﹤0.01% 2237
2023
Q4 		$2.83M Buy
157,640
+113,012
+253% +$1.99M ﹤0.01% 2395
2023
Q3 		$735K Buy
+44,628
New +$809K ﹤0.01% 3249
2023
Q1 		– Sell
-12,249
Closed -$278K – 4791
2022
Q4 		$278K Sell
12,249
-4,200
-26% -$94.9K ﹤0.01% 4118
2022
Q3 		$435K Buy
+16,449
New +$488K ﹤0.01% 4119
2021
Q4 		– Sell
-60,303
Closed -$2.53M – 5664
2021
Q3 		$2.53M Sell
60,303
-201,467
-77% -$7.25M ﹤0.01% 2814
2021
Q2 		$10.2M Buy
261,770
+5,545
+2% +$198K 0.01% 1480
2021
Q1 		$8.74M Buy
256,225
+110,838
+76% +$4.73M 0.01% 1450
2020
Q4 		$6.59M Buy
145,387
+9,908
+7% +$346K 0.01% 1665
2020
Q3 		$3.73M Buy
135,479
+28,398
+27% +$926K ﹤0.01% 1912
2020
Q2 		$3.94M Buy
107,081
+14,918
+16% +$556K ﹤0.01% 1843
2020
Q1 		$2.98M Buy
92,163
+68,402
+288% +$2.85M ﹤0.01% 1862
2019
Q4 		$973K Sell
23,761
-11,514
-33% -$455K ﹤0.01% 3006
2019
Q3 		$1.26M Sell
35,275
-9,125
-21% -$370K ﹤0.01% 2697
2019
Q2 		$2.28M Buy
+44,400
New +$2.22M ﹤0.01% 2151
2017
Q4 		– Sell
-9,516
Closed -$314K – 3713
2017
Q3 		$314K Buy
+9,516
New +$214K ﹤0.01% 3124
2016
Q1 		– Sell
-29,907
Closed -$496K – 3721
2015
Q4 		$496K Buy
+29,907
New +$594K ﹤0.01% 3098

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's RGNX Position: Q1 2026 in Review

D.E. Shaw & Co increased its Regenxbio (RGNX) stake by 318% in Q1 2026, buying an estimated $2.29M and bringing the position to 286,001 shares worth $2.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2777.

D.E. Shaw & Co first reported a position in RGNX in Q4 2015 and has held it in 22 quarters since. The position peaked at $10.2M in Q2 2021. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • D.E. Shaw & Co held 286,001 shares of Regenxbio worth $2.4M as of Q1 2026.
  • D.E. Shaw & Co bought 217,613 Regenxbio shares in Q1 2026, an estimated $2.29M.
  • Regenxbio made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2777 holding.
  • D.E. Shaw & Co first reported a position in Regenxbio in Q4 2015 and has held it in 22 quarters since.
  • D.E. Shaw & Co's Regenxbio position peaked at $10.2M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.